With a current ratio slightly above 1.0, liquidity is adequate but not strong, suggesting the company can cover short-term liabilities but with limited cushion.

The quick ratio mirrors the current ratio, indicating the company can meet short-term obligations without relying on inventory, which is typical for a service-based healthcare insurer.

Liquidity has improved moderately over the past year from below 1.0 towards just over 1.0, indicating steady improvements in working capital management.

Short-term risk of cash crunch appears low given positive interest coverage and liquidity above 1.0, though limited buffer leaves little room for unexpected cash flow disruptions.

The debt-to-equity ratio remains low around 0.26, reflecting a conservative capital structure and limited reliance on debt financing compared to typical insurance industry norms.

Low debt-to-assets ratio (~4.6%) confirms minimal leverage, consistent with a capital-light business model focusing on managed care services rather than heavy fixed asset investment.

High interest coverage ratio (~131x) indicates the company can comfortably service its debt obligations with substantial earnings buffer, reducing solvency risk.

Long-term financial health depends on sustained profitability and membership base growth; current solvency is solid but contingent on execution and regulatory environment stability.

The beta is not provided here explicitly, but market volatility and technical patterns suggest moderate market correlation typical of growth-oriented healthcare insurers.

Relative to peers, OSCR may exhibit higher volatility given its growth-stage status and exposure to regulatory and enrollment uncertainties inherent to ACA marketplace dependence.

OSCR is sensitive to changes in healthcare policy, ACA subsidy frameworks, and macroeconomic factors affecting consumer insurance purchasing behavior, with some sensitivity to interest rates through cost of capital concerns.

If Oscar Health successfully navigates ACA enrollment challenges and operational efficiencies materialize via tech and AI initiatives, earnings could improve markedly, driving multiple expansion and price appreciation.

Failure to sustain membership, manage medical loss ratios, or adverse policy changes could depress revenues and margins, leading to significant downside from current price levels.

The moderate risk is balanced by material upside potential tied to market growth and digital health innovation, though near-term volatility and operational execution risks prevent a low-risk profile.

Investors may consider a moderate position size to capitalize on growth potential while mitigating downside from regulatory and enrollment risks, suitable for medium to long-term horizons.